Teva Pharmaceutical Industries (TEVA) said late Thursday it has agreed to divest all shares of Teva Takeda Pharma and its Teva Takeda Yakuhin subsidiary to JKI, which was established by the fund managed and operated by J-Will Partners.
Financial terms were not disclosed.
All the employees of the transferred business venture will remain employed, the company said.
Teva said the divestment, expected to be completed by April 1, will allow it to focus on its medicines business in Japan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.